Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Investing.com -- Autonomix Medical Inc (NASDAQ:AMIX) stock gained 4.1% on Thursday after the company announced it had secured a new patent for its precision nerve-targeting technology focused on cardiac treatments.
The medical device company, which specializes in nerve-targeted treatments, received U.S. Patent No. 12,369,852 from the United States Patent and Trademark Office. The patent covers systems and methods that sense autonomic cardiac signals, map targets, and deliver therapy with closed-loop feedback for precise treatment of cardiac tissues.
The newly patented technology is designed to perform feedback-driven neuromodulation, denervation, and ablation of tissues. According to the company, this approach could potentially transform treatment in several high-growth cardiology areas, including renal denervation for hypertension, arrhythmia management, heart failure, and refractory angina.
Brad Hauser, CEO of Autonomix, stated that the autonomic nervous system plays a major role in regulating cardiac activity, and their technology could provide precision nerve-targeted therapies with fewer complications compared to current treatments like sympathetic beta-receptor blockade, which affects all cells and organs in the body.
The patent specifically addresses applications across various cardiac conditions, including atrial and ventricular arrhythmias, ischemia/angina, coronary spasm, myocardial infarction risk modulation, heart failure, and hypertension. The company suggests its approach may reduce dependence on systemic beta blockade and its associated side effects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.